// App-Quantinova.ai

9065 : Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

Researchers

Presenter

  • Caroline Elizabeth McCoach

Principal Investigators

  • Anh T. Le

  • Dara Aisner

  • Katherine Gowan

  • Kenneth L Jones

  • Dan Merrick

  • Paul A. Bunn

  • William T. Purcell

  • Marileila Varella-Garcia

  • D. Ross Camidge

  • Robert Charles Doebele

Medical Centers

  • University of Colorado Denver School of Medicine, Aurora, CO

  • University of Colorado Anschutz Medical Campus, Aurora, CO

  • University of Colorado Cancer Center, Aurora, CO

  • University of Colorado Cancer Center, Aurora, CO

  • University of Colorado Cancer Center, Aurora, CO

  • University of Colorado Cancer Center, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Epidermal growth factor receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved